NewsRoom Articles - Page 15 of 23

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumorsGlioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cureCNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, BerubicinBerubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclinesCNS has shown evidence of slowing disease progression…

ThursdaySep 08, 2022 9:45 am

Cepton, Inc.’s (NASDAQ: CPTN) Short-Range Lidar Nova Aims to Eliminate Blind Spots for Autonomous Vehicles; Plans to Exhibit Tech During IAA Transportation Conference

Cepton, in collaboration with ZKW Group GmbH, plans to showcase its Nova lidar headlamp integration into a ZKW heavy-duty truck headlamp at the IAA Transportation Conference (Sept. 20-25, 2022)Nova is an award-winning, miniature, wide field of view, near-range lidar sensor that provides high resolution 3D imaging in a compact form factor Nova integrates seamlessly around vehicles to provide 360-degree perception boosting blind spot detection, which is becoming a mandated vehicle safety feature The success of autonomous vehicles (“AV”) and advanced driver assistance systems (“ADAS”) hinges on technologies that make 360-degree intelligent perception possible. Cepton (NASDAQ: CPTN), a Silicon Valley innovator of…

ThursdaySep 08, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Names New CFO, Process for Ensuring Smooth Transition Amid Company’s Global Growth

Global cannabis brand-builder Flora Growth recently named a former Amazon financial executive as its new CFO Elshad Garayev will work with outgoing CFO Lee Leiderman to ensure a smooth transition of responsibility amid finalization of Flora’s mid-year financial filing with the SECFlora Growth is headquartered in Canada with cultivation operations centered in Colombia, where recent government administrations have opened regulatory processes for exporting cannabis derivatives for the health and wellness marketsThe company continues to expand its operations internationally for sales in the UK and Europe generally, Australia, and throughout the Americas Global cannabis brand-builder Flora Growth (NASDAQ: FLGC) has steadily built…

WednesdaySep 07, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 millionThe company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar yearCNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics approvals specifically…

TuesdaySep 06, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability

Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technologyThe company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffnessAlthough hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under controlA Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effectsLexaria’s DehydraTECH-CBD may well be the solution…

FridaySep 02, 2022 9:15 am

B2B iGaming Leader Golden Matrix Group Inc. (NASDAQ: GMGI) To Enter B2C Market with Recent Permit Approval

GMGI acquired 80% stake in RKings social gaming platform that earned $32 million in revenue and $2.6 million in net income during fiscal 2021Permit application for Mexico approved others to follow as more governments legalize online gamblingOnline gambling revenues expected to reach $153.6 billion by 2030 at CAGR of 11.7 percent from 2022 to 2030 Golden Matrix Group (NASDAQ: GMGI), an iGaming leader based in Las Vegas, develops, and owns online gaming IP, turnkey online casino solutions, and configurable, scalable white-label gaming platforms for international gaming operators. The company’s extensive portfolio of proprietary technology has made it a leader in…

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”)So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancerIt remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to patients and…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybinThese results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybinAfter receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol use disorder…

WednesdayAug 31, 2022 9:15 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Set to Capitalize on US Online Gaming Boom

Commercial gaming revenues in the United States reached a record $14.81bn in 2Q22Online gaming operations grew at an even faster pace, rising by 34.3% YoY to all-time high of $1.21 billionRecent studies have found that the online gaming market space within the United States could triple in size over the next five years, growing to $24.3 billion by 2026Golden Matrix Group, which recently won its Mexican gaming permit, looks well positioned to capitalize on the growth of the US online gaming sector through its B2B white-labelling operations Commercial gaming revenue in the United States reached a record $14.81 billion in…

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”)GBM is an aggressive form of cancer that occurs in the brain or spinal cordIn the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosisCNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical stage biotechnology company…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717